Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344624 | 1.00 | GABRA1 (0.42) | GABRA1GABRB1UGT2B7CYP3A4TSHR | |
| SCHEMBL19667844 | 0.94 | GABRA1 (0.42) | GABRA1GABRB1UGT2B7CYP3A4TSHR | |
| SCHEMBL19707538 | 0.85 | GABRA1 (0.37) | GABRA1GABRB1UGT2B7 | |
| SCHEMBL2422394 | 0.84 | GABRA1 (0.35) | GABRA1GABRB1UGT2B7MEN1KMT2A | |
| SCHEMBL28989624 | 0.84 | GABRA1 (0.35) | GABRA1GABRB1UGT2B7MEN1KMT2A | |
| SCHEMBL14202010 | 0.80 | GABRA1 (0.33) | GABRA1GABRB1UGT2B7 | |
| SCHEMBL14918336 | 0.80 | GABRA1 (0.37) | GABRA1GABRB1UGT2B7 | |
| SCHEMBL3584815 | 0.79 | NOTUM (0.45) | GABRA1GABRB1 | |
| SCHEMBL631573 | 0.79 | NOTUM (0.45) | GABRA1GABRB1 | |
| SCHEMBL3594814 | 0.79 | NOTUM (0.45) | GABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2024-06-06 | — | — | US | disclosed |
| EP-4303216-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-01-10 | — | — | EP | disclosed |
| CN-116981661-A | Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| EP-0579618-B1 | PYRIDINE- AND IMIDAZOLE-DERIVED AGENTS FOR CARDIOVASCULAR DISEASES | PFIZER LTD (GB) | 1999-10-13 | — | — | EP | disclosed |
| US-5705523-A | THROMBOXANE A2 SYNTHETASE INHIBITORS | PFIZER INC. (US) | 1998-01-06 | — | — | US | disclosed |
| US-5457118-A | Pyridine derived agents for cardiovascular diseases | PFIZER INC. (US) | 1995-10-10 | — | — | US | disclosed |
| EP-0579618-A1 | PYRIDINE- AND IMIDAZOLE-DERIVED AGENTS FOR CARDIOVASCULAR DISEASES | Pfizer Limited (GB) | 1994-01-26 | — | — | EP | disclosed |
| WO-1992017451-A1 | PYRIDINE- AND IMIDAZOLE-DERIVED AGENTS FOR CARDIOVASCULAR DISEASES | PFIZER LIMITED (GB) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, HASPIN | GABRA1 3436/4885GABRB1 3060/4885UGT2B7 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.